Ratio-Ipratropium UDV · DIN 02097168 · 250mcg/mL · Inh Sol-2mL UDV Pk
Limited Use — Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.Discontinued 2018-05-18 · checked 2026-09-19
StatusLimited Use — Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Write on scriptLU code 265, 266, 267, 268 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Ipratropium UDV · DIN 02097168
Manufacturer: Ratiopharm Inc.; listing date 1996-12-19
Health Canada: Cancelled post market since 2018-05-18 · brand RATIO-IPRATROPIUM UDV · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Ratio-Ipratropium UDV: Formulary list price $1.3180/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3180 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19798 · Verify on the e-Formulary ↗ (DIN 02097168)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02097168).
DIN 02097168: Ratio-Ipratropium UDV
Raw flags: dinStatus=E, sec12=Y, sec3=Y
Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id RPH
Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed
Source prices (unrounded): $1.3180; ministry $1.3180
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02097168
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19798
Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded
PMS-Ipratropium · DIN 02231245 · $1.3180
Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.